Founded in 2001 with the promise to revolutionize medication adherence, Proteus successfully developed a technology making it possible to accurately track pill ingestions. The company’s efforts led the US Food and Drug Administration (FDA) to clear Proteus technology in July 2012 for commercial use and create a new category for Ingestible Biomedical Sensors. In partnership with Otsuka, a Japanese drug manufacturer with a strong presence in Mental Health, Proteus gained a new FDA clearance in November 2017 for the first Digital Medicine System.

I joined Proteus in October 2017 to lead the UX Foundations team and spearheaded the definition and design of the first medication adherence solution for Oncology. The 9 month project begun with User Research and Discovery with Dr. Sutton with the Duke Cancer Network and Dr. Greeno and his team at the Masonic Cancer Center of the University of Minnesota. In September 2018, our first patient begun successfully using Proteus Discover for Oncology.

Following the departure of the VP of Design, I was given the opportunity to step up as Head of Design leading a team of 18 Product Designers and User Researchers. This shift in responsibilities translated into a re-focus of my attention on Design Ops, Research Ops and the launch of a Design System.